A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort
|First Received Date ICMJE||December 22, 2005|
|Last Updated Date||April 4, 2007|
|Start Date ICMJE||December 2005|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE
||To compare the tolerability and acceptance of patients on the Kaletra® soft gel with that of Kaletra® tablet formulation utilizing the Symptoms Distress Module developed by the ACTG and the Center Epidemiological S|
|Original Primary Outcome Measures ICMJE
||The primary objective of this study is to compare the tolerability and acceptance of patients on the Kaletra® soft gel with that of Kaletra® tablet formulation utilizing the Symptoms Distress Module developed by the ACTG and the Center Epidemiological S|
|Change History||Complete list of historical versions of study NCT00268827 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
||Proportion of subjects maintaining or achieving HIV-RNA < 400 or < 50 copies/ml, maintaining or increasing CD4 T-lymphocyte count;G.I. or other adverse events grade 2-4;Other adverse events|
|Original Secondary Outcome Measures ICMJE
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort|
|Official Title ICMJE||A Comparison of Adverse Events and Quality of Life Before and After Switching From Kaletra Soft-Gel Capsules (SGC) to Kaletra Tablets in an African American Cohort|
|Brief Summary||The purpose of this study is to compare Kaletra tablets with Kaletra soft-gel capsules to see if there is any change in the side effects you may have and to see how people in the study feel about using the tablets.|
The demand for once-a-day easily tolerated therapies is increasing. While Abbott Laboratories 418 study has demonstrated the efficacy of Kaletra® with both BID and QD dosing with capsules, the pill count of QD dosing may decrease its attractiveness for this population. In some patients, issues such as diarrhea, nausea, food restrictions, or the need to refrigerate their medication may also impact quality of life and possibly lead to non adherence and ultimately treatment failure. Moreover, it is believed that the diarrhea associated with Kaletra® capsules may be the result of capsule excipients that are unrelated to the active drug.
Kaletra® has a long track record of being highly potent and not selective for protease inhibitor resistance as evidence by the Phase II Study 720. The results of this study demonstrate that ABT-378/ritonavir therapy is highly potent, durable, and well tolerated when administered concomitantly with two nucleoside analog reverse transcriptase inhibitors to antiretroviral-naïve HIV-1 infected individuals. A high proportion of subjects achieved normal viral suppression (< 50 copies/ml – 78% by ITT). No discontinuations due to study drug -related clinical or laboratory adverse events occurred during the first 48 weeks of study but the most common adverse effect was diarrhea (25%). Given the high oleic content of the capsules, dosing all six capsules at once may cause a “bolus” of this acid leading to increased diarrhea. Because of the viral suppression advantages, there is desire to see if there is a difference in quality of life and tolerability between the soft-gel capsules and the new tablet formulation of Kaletra® which allows for fewer tablets per day and does not include additives possibly associated with increased diarrhea.
Study MOO-267 (PLATO), a multi-center study evaluated and demonstrated improved quality of life when switching from other regimens (efavirenz, nevirapine, indinavir, and nelfinavir) to Kaletra®. Instruments used to measure change in quality of life included the AIDS Clinical Trial Group (ACTG) Symptom Distress Module (ASDM) which measures the presence of bothersome symptoms commonly seen with HIV and ARV treatment; the Medical Outcomes Study-HIV Health Survey (MOS-HIV) which is widely used to evaluate the Quality of Life (QOL) of HIV infected patients; and the Center for Epidemiological Studies and Depression (CES-D), a validated self-reporting questionnaire used as a screening tool for depression.
The hypothesis is that patient’s quality of life will improve when switched from Kaletra® soft-gel to Kaletra® tablets. The tablet formulation of Kaletra® will improve quality of life by simplifying current HAART regimens by decreasing pill count, improving tolerability, eliminating food restrictions and the need for drug refrigeration. African-American subjects were selected for this study because they are an understudied population and due to adherence behavior. In reviewing Abbott Study 418 and Study MOO 267 the percent of African-American enrollees accounted for 27% and 15% of the study groups respectively.1,4 In studies where there is an association between socio demographic factors and adherence behavior, the direction is consistent: younger age, non-white race, lower income, lower literacy and unstable housing was associated with non-adherence. Adherence behavior refers to the extent to which patients take their medication as prescribed by their health provider. As stated above, patients who are younger, non white race, lower income and live in unstable housing are less likely to adhere to the prescribed medication regime. It is important to evaluate antiretroviral therapy formulations to validate patient tolerability and acceptance in order to promote drug adherence. This study will compare the tolerability and acceptance of patients on Kaletra® soft-gel capsules with that of Kaletra® tablet formulation utilizing validated instruments as described above.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 4|
|Study Design ICMJE||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Study Arms||Not Provided|
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||February 2006|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
Inclusion Criteria:1. African American male or female patients ≥ 18 years of age 2. Documented HIV-infected 3. Currently on Kaletra® soft-gel capsules for >2 weeks 4. Competent and willingness to sign and date a written informed consent 5. No recent acute illness in the preceding 30 days which in the opinion of the investigator would preclude inclusion in the study 6. No current gastrointestinal symptoms at baseline of grade II or greater 7. A female is eligible to enter and participate in this study if she is of:
NOTE: Data are insufficient to exclude a clinically important interaction of LPV/r with drugs, such as hormonal contraceptives, that are highly metabolized by the cytochrome P450 enzyme system. As a result, hormonal contraception is not considered adequate.
Exclusion Criteria:1. Positive pregnancy test or breast-feeding 2. Known hypersensitivity to study medications 3. Inability to conform to protocol procedures, including alcohol or drug abuse, untreated psychiatric illness 4. An unwillingness or presence of any condition that will impair the ability to swallow medications 5. Patient has required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to entry, or has an anticipated need for these agents within the study period.
6. Patient requires treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, or interferon’s within 4 weeks prior to study entry, or patients who have received an HIV immunotherapeutic vaccine within 3 months prior to entry.
7. Patient requires inhaled or intranasal fluticasone
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00268827|
|Other Study ID Numbers ICMJE||70-1002-070
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Not Provided|
|Study Sponsor ICMJE||AIDS Arms Inc.|
|Collaborators ICMJE||Not Provided|
|PRS Account||AIDS Arms Inc.|
|Verification Date||April 2007|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP